AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.64
-0.68 (-6.01%)
At close: Apr 28, 2026, 4:00 PM EDT
10.11
-0.53 (-4.98%)
After-hours: Apr 28, 2026, 4:20 PM EDT
AgomAb Therapeutics NV Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for AgomAb Therapeutics NV stock have an average target of 32, with a low estimate of 28 and a high estimate of 36. The average target predicts an increase of 200.75% from the current stock price of 10.64.
Analyst Consensus: Buy
* Price targets were last updated on Mar 3, 2026.
Analyst Ratings
The average analyst rating for AgomAb Therapeutics NV stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 3 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $36 | Buy | Initiates | $36 | +238.35% | Mar 3, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $32 | Buy | Initiates | $32 | +200.75% | Mar 3, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $28 | Buy | Initiates | $28 | +163.16% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
1.43M
Revenue Next Year
1.68M
from 1.43M
Increased by 17.86%
EPS This Year
-1.63
from -115.59
EPS Next Year
-1.72
from -1.63
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.9M | 3.5M | ||||||
| Avg | 1.4M | 1.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 142.6% | ||||||
| Avg | - | 17.9% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -1.38 | -1.34 |
| Avg | -1.63 | -1.72 |
| Low | -1.85 | -2.06 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.